Cimino fistula

IN.PACT™ AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

Retrieved on: 
Tuesday, April 20, 2021

"Being able to show these results at two years will ultimately impact standard of care for patients undergoing dialysis.

Key Points: 
  • "Being able to show these results at two years will ultimately impact standard of care for patients undergoing dialysis.
  • For my patients, these durable results translate into fewer reinterventions and a better quality of life.
  • Over time, vessel restenosis limits the ability to use AV fistulae effectively.
  • The Lutonix AV Randomized Trial of Paclitaxel-Coated Balloons in Arteriovenous Fistula Stenosis: 2-Year Results and Subgroup Analysis.

Stanford Surgeon Venita Chandra Joins Alucent Biomedical Scientific Advisory Board as Company Enters Arteriovenous Fistula Market

Retrieved on: 
Tuesday, December 8, 2020

Alucent Biomedical , a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D.

Key Points: 
  • Alucent Biomedical , a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D.
  • The company announced today it will also seek to adapt the technology for another use, the maturation and preservation of arteriovenous fistula (AVF) for hemodialysis (HD).
  • Applying the treatment at fistula creation has facilitated maturation and the promotion of outward remodeling of the AVF, Dr. Chandra said.
  • Alucent was founded by Avera Health to develop and market products using Alucent Natural Vascular Scaffolding (Alucent NVS) technology.

Minimally Invasive Ellipsys System Creates Fused, Permanent Vascular Access for Dialysis

Retrieved on: 
Friday, October 30, 2020

SAN JUAN CAPISTRANO, Calif., Oct. 30, 2020 /PRNewswire/ --A new case report published in the Journal of Vascular Surgery provides one of the first known opportunities to directly visualize the permanent and fused connection (anastomosis) that is created with the minimally invasive Ellipsys Vascular Access System.

Key Points: 
  • SAN JUAN CAPISTRANO, Calif., Oct. 30, 2020 /PRNewswire/ --A new case report published in the Journal of Vascular Surgery provides one of the first known opportunities to directly visualize the permanent and fused connection (anastomosis) that is created with the minimally invasive Ellipsys Vascular Access System.
  • The Ellipsys System, made by Avenu Medical, creates a type of dialysis access known as a percutaneous arteriovenous fistula (pAVF) for patients with end-stage renal disease (ESRD) who require hemodialysis.
  • Dr. Mallios has published numerous studies showing the ability of the Ellipsys System to easily and safely create durable vascular access for ESRD patients.
  • The company's Ellipsys Vascular Access System is an innovative, ultrasound-guided, single-catheter endoAVF system used to percutaneously create an arteriovenous fistula for hemodialysis access.

Ellipsys System Offers Greater Patient Eligibility and Reduced Time to Dialysis

Retrieved on: 
Thursday, September 10, 2020

The Ellipsys System had a technical success rate of 100 percent, and only 27.7 percent of patients required secondary interventions following fistula creation.

Key Points: 
  • The Ellipsys System had a technical success rate of 100 percent, and only 27.7 percent of patients required secondary interventions following fistula creation.
  • Overall, 79.5 percent of Ellipsys patients and 58 percent of WavelinQ patients were able to successfully begin dialysis with their fistula.
  • "For every patient, my goal is to create the best possible dialysis access with the fewest possible interventions," said Dr. Shahverdyan.
  • The company's Ellipsys Vascular Access System is an innovative, ultrasound-guided, single-catheter endoAVF system used to percutaneously create an arteriovenous fistula for hemodialysis access.

Ellipsys System Offers Significant Advantages for Creating Dialysis Access, Physicians Say

Retrieved on: 
Tuesday, March 3, 2020

Accelerating this process is important because it can potentially reduce the length of time patients require a catheter for dialysis.

Key Points: 
  • Accelerating this process is important because it can potentially reduce the length of time patients require a catheter for dialysis.
  • "Ellipsys enables us to streamline the dialysis timeline and reduce patients' total catheter contact by a significant amountsometimes by as much as four months.
  • Hull, Dr. Cooper and Dr. Rajeev Narayan trained more than 70 physicians on the Ellipsys System at a hands-on endoAVF workshop.
  • The company's Ellipsys Vascular Access System is an innovative, ultrasound-guided, single catheter endoAVF system used to percutaneously create an arteriovenous (AV) fistula for hemodialysis access.

VasQ™ External Support demonstrates significant improvement in fistula usability in the newly published multi-center randomized-controlled study

Retrieved on: 
Friday, August 23, 2019

Laminate Medical Technologies (Laminate) has announced that the American Journal of Kidney Disease has published the first multi-center, randomized-controlled study of the VasQ External Support for newly created arteriovenous fistulas in hemodialysis patients.

Key Points: 
  • Laminate Medical Technologies (Laminate) has announced that the American Journal of Kidney Disease has published the first multi-center, randomized-controlled study of the VasQ External Support for newly created arteriovenous fistulas in hemodialysis patients.
  • The results of the newly published study demonstrate a significant improvement in fistulas becoming functional with VasQ as compared to the standard of care.
  • The outcomes demonstrated significant improvement in functional patency with increased intra-luminal vein diameters in the cannulation segment (a key factor to enable good fistula function) at 3-months post fistula creation.
  • Conversely, stenosis (the leading cause of fistula failure) occurred in 15% of VasQ patients as opposed to 50% of control (P = .04).

FDA permits marketing of first catheter-based systems used to create vascular access for hemodialysis patients

Retrieved on: 
Friday, June 22, 2018

Specifically, the FDA granted marketing authorization for the use of the Ellipsys Vascular Access System and the everlinQ endoAVF System to make what's called an arteriovenous (AV) fistula for patients who need hemodialysis access.

Key Points: 
  • Specifically, the FDA granted marketing authorization for the use of the Ellipsys Vascular Access System and the everlinQ endoAVF System to make what's called an arteriovenous (AV) fistula for patients who need hemodialysis access.
  • For the Ellipsys Vascular Access System, the FDA reviewed data from a non-randomized, multi-center study of 103 patients.
  • The everlinQ endoAVF System was used in a procedure to create an AV fistula in these patients.
  • The FDA granted marketing authorization of the Ellipsys Vascular Access System to Avenu Medical.